Original Research
Published on 11 Jun 2025
Peripheral blood inflammatory score using a cytokine multiplex assay predicts clinical outcomes in patients treated with atezolizumab-bevacizumab for unresectable HCC
in Cancer Immunity and Immunotherapy
Frontiers in Immunology
doi 10.3389/fimmu.2025.1578422
- 3,928 views
- 3 citations
